The abstract is read at the publisher; the summary is JClub's.
Consolidation durvalumab after concurrent chemoradiotherapy in limited-stage small-cell lung cancer is linked to lower extrathoracic progression (20.1% vs 30.1%) and longer time to progression or death.
- Why it matters: Post-hoc progression patterns were needed to clarify where disease recurs after cCRT and whether durvalumab shifts progression beyond the thorax.
- What they did: In the ADRIATIC phase 3 trial, patients randomized to durvalumab (n=264) or placebo (n=266) were followed until progression or toxicity; first progression sites were classified by BICR using RECIST v1.1 and analyzed with Kaplan–Meier.
- The result: Time to extrathoracic progression or death favored durvalumab (HR 0.68 [95% CI 0.49–0.93]), and time including brain progression or death also favored durvalumab (HR 0.64 [95% CI 0.40–1.01]).
The findingWhy it mattersWhat they didThe result
AI summary of the abstract · may contain errors · not medical advice · read the paper.